BR112012006233B8 - composto de fórmula i, composição farmacêutica e usos de um composto - Google Patents

composto de fórmula i, composição farmacêutica e usos de um composto

Info

Publication number
BR112012006233B8
BR112012006233B8 BR112012006233A BR112012006233A BR112012006233B8 BR 112012006233 B8 BR112012006233 B8 BR 112012006233B8 BR 112012006233 A BR112012006233 A BR 112012006233A BR 112012006233 A BR112012006233 A BR 112012006233A BR 112012006233 B8 BR112012006233 B8 BR 112012006233B8
Authority
BR
Brazil
Prior art keywords
compound
compounds
formula
pharmaceutical composition
present
Prior art date
Application number
BR112012006233A
Other languages
English (en)
Other versions
BR112012006233A2 (pt
BR112012006233B1 (pt
Inventor
Chaudhari Anita
Mohanan Anookh
Dutt Chaitanya
Chhipa Laxmikant
Badanthadka Murali
G Jamadarkhana Prashant
Chandra Gupta Ramesh
Srivastava Sanjay
Deshpande Shailesh
Chauthaiwale Vijay
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of BR112012006233A2 publication Critical patent/BR112012006233A2/pt
Publication of BR112012006233B1 publication Critical patent/BR112012006233B1/pt
Publication of BR112012006233B8 publication Critical patent/BR112012006233B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/16—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

composto de fórmula i, composição farmacêutica e usos de um composto a presente invenção refere-se a compostos, seus sais farmaceuticamente aceitáveis, e seus isômeros, esteroisômeros, confôrmeros, tautômeros, polimorfos, hidratos e solvatos. a presente invenção também abrange composições farmaceuticamente aceitáveis dos ditos compostos e um processo para preparar ditos compostos. a presente invenção refere-se, ainda, ao uso dos compostos supracitados para a preparação de medicamento para uso como produtos farmacêuticos.
BR112012006233A 2009-10-13 2010-08-31 composto de fórmula i, composição farmacêutica e usos de um composto BR112012006233B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1249/KOL/2009 2009-10-13
IN1249KO2009 2009-10-13
PCT/IN2010/000579 WO2011045811A1 (en) 2009-10-13 2010-08-31 Fused thiazolo and oxazolo pyrimidinones

Publications (3)

Publication Number Publication Date
BR112012006233A2 BR112012006233A2 (pt) 2020-08-11
BR112012006233B1 BR112012006233B1 (pt) 2021-05-18
BR112012006233B8 true BR112012006233B8 (pt) 2021-05-25

Family

ID=43034589

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012006233A BR112012006233B8 (pt) 2009-10-13 2010-08-31 composto de fórmula i, composição farmacêutica e usos de um composto

Country Status (27)

Country Link
EP (1) EP2385948B1 (pt)
JP (1) JP5681195B2 (pt)
KR (1) KR101710430B1 (pt)
CN (1) CN102549000B (pt)
AR (1) AR080616A1 (pt)
AU (1) AU2010307984B2 (pt)
BR (1) BR112012006233B8 (pt)
CA (1) CA2772995C (pt)
CY (1) CY1119710T1 (pt)
DK (1) DK2385948T3 (pt)
EA (1) EA020228B1 (pt)
ES (1) ES2653931T3 (pt)
HR (1) HRP20171976T1 (pt)
HU (1) HUE038051T2 (pt)
IL (1) IL219116A (pt)
LT (1) LT2385948T (pt)
MX (1) MX2012004074A (pt)
MY (1) MY157629A (pt)
NO (1) NO2385948T3 (pt)
NZ (1) NZ598020A (pt)
PL (1) PL2385948T3 (pt)
RS (1) RS56630B1 (pt)
SI (1) SI2385948T1 (pt)
TW (1) TWI500623B (pt)
UA (1) UA107473C2 (pt)
WO (1) WO2011045811A1 (pt)
ZA (1) ZA201203262B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI661828B (zh) 2013-05-14 2019-06-11 印度商托仁特生技有限公司 低劑量藥物組合物及其用途
AU2015311333B2 (en) 2014-09-02 2017-11-16 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
CN106905348B (zh) * 2017-02-13 2018-12-04 牡丹江医学院 一种预防和治疗急性肾损伤的药物及其制备方法和用途
CN110511233B (zh) * 2019-08-08 2022-01-25 成都大学 一种噻唑并[2,3-b]噁唑酮类化合物及其制备方法和用途
CN112778333B (zh) * 2021-01-23 2022-07-05 中国科学院新疆理化技术研究所 一种四氢噁唑并吡啶并氮氧杂酮类衍生物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072679A (en) * 1976-06-15 1978-02-07 E. R. Squibb & Sons, Inc. 1,4- AND 4,10-DIHYDRO-4-OXO-PYRIMIDO (1,2-A)-benzimidazole-3-carboxylic acids, esters and amides
US4423048A (en) 1979-11-23 1983-12-27 Pfizer Inc. Antiallergic and antiulcer 1-oxo-1H-thiazolo[3,2-a]pyrimidine-2-carboxamides and intermediates therefor
DK151811C (da) * 1979-11-23 1988-06-06 Pfizer Analogifremgangsmaade til fremstilling af n-(5-tetrazolyl)-1-oxo-1h-thiazolooe3,2-aaa-pyrimidin-2-carboxamider eller farmaceutisk acceptable kationsalte deraf samt 1-oxo-1h-thiazolooe3,2-aaapyrimidin-2-carboxylsyrer til anvendelse som udgangsmaterialer ved fremgangsmaaden
JPH0539293A (ja) * 1991-01-23 1993-02-19 Kyowa Hakko Kogyo Co Ltd 免疫調節剤及びチアゾロピリミジン誘導体
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
CA3094774A1 (en) 2001-12-06 2003-07-03 Fibrogen, Inc. Use of hif prolyl hydroxylase inhibitors for treating neurological disorders
CA2511493A1 (en) 2002-12-25 2004-07-15 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
JP5111491B2 (ja) * 2006-04-04 2013-01-09 フィブロジェン， インコーポレイテッド ピロロ−およびピラゾロ−ピリミジン化合物、およびそれらの使用方法
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
AR061570A1 (es) * 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
WO2009039322A1 (en) * 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039321A1 (en) * 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors

Also Published As

Publication number Publication date
NZ598020A (en) 2013-11-29
HUE038051T2 (hu) 2018-10-29
AU2010307984B2 (en) 2013-11-07
SI2385948T1 (en) 2018-04-30
ZA201203262B (en) 2013-01-30
EA020228B1 (ru) 2014-09-30
PL2385948T3 (pl) 2018-02-28
CA2772995C (en) 2018-03-13
CN102549000A (zh) 2012-07-04
EP2385948B1 (en) 2017-10-04
ES2653931T3 (es) 2018-02-09
JP5681195B2 (ja) 2015-03-04
EP2385948A1 (en) 2011-11-16
RS56630B1 (sr) 2018-03-30
WO2011045811A1 (en) 2011-04-21
TWI500623B (zh) 2015-09-21
LT2385948T (lt) 2018-01-10
BR112012006233A2 (pt) 2020-08-11
MY157629A (en) 2016-07-15
IL219116A (en) 2016-05-31
HRP20171976T1 (hr) 2018-02-09
JP2013507435A (ja) 2013-03-04
BR112012006233B1 (pt) 2021-05-18
CA2772995A1 (en) 2011-04-21
CN102549000B (zh) 2015-12-02
IL219116A0 (en) 2012-06-28
KR20120093907A (ko) 2012-08-23
DK2385948T3 (en) 2017-12-04
EA201270556A1 (ru) 2013-01-30
AR080616A1 (es) 2012-04-25
TW201113290A (en) 2011-04-16
NO2385948T3 (pt) 2018-03-03
UA107473C2 (uk) 2015-01-12
CY1119710T1 (el) 2018-06-27
AU2010307984A1 (en) 2012-03-01
MX2012004074A (es) 2012-05-22
KR101710430B1 (ko) 2017-02-27

Similar Documents

Publication Publication Date Title
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
BR112015012425A2 (pt) composto, composição farmacêutica, método e medicamento para o tratamento de doenças medicadas pela proteína parp-1 e uso do composto
CR20120237A (es) Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos
UY33731A (es) ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep?
BR112015014222A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de anemia e composição farmacêutica
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
EA201490807A1 (ru) Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1
ECSP12012334A (es) Morfolinopirimidinas y su uso en terapia
BR112014011850A8 (pt) Derivados de aminopirimidina, seus usos, e composição farmacêutica
WO2009125434A3 (en) Oxime derivatives, process for their preparation, pharmaceutical composition containing the same and medicinal use thereof
MX2012002997A (es) Derivados de eter de los heteroarilos biciclicos.
BRPI1007092B8 (pt) Derivados de hidroxamato, uso dos derivados de hidroxamato, composições farmacêuticas e método de produção de derivados de hidroxamato
BR112013025128A2 (pt) derivados de pirrol como moduladores de receptor de acetilcolina nicotínico para uso no tratamento de distúrbios neurodegenenerativos tal como doença de alzheimer e doença de parkinson
BR112014001083B8 (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
GT201300322A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
BR112012006233B8 (pt) composto de fórmula i, composição farmacêutica e usos de um composto
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
BR112014006643A2 (pt) compostos de imidazopiridina, composições e métodos de uso dos mesmos
BR112013012665A2 (pt) composto de fórmula (i), ou um sal, pró-droga ou solvato do mesmo e composição farmacêutica
WO2011087712A3 (en) Tricyclic derivatives and their pharmaceutical use and compositions
GEP20156269B (en) New secondary 8-hydroxyquinoline-7- carboxamide derivatives
BR112012028376A2 (pt) derivado inusitado da síntese de ecdisterona, seu método de preparação e uso.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/08/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/08/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF